Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lab study reveals how HIV drug crosses the placenta

NCT ID NCT02020083

Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study used donated placentas from 369 pregnant women to understand how the HIV drug tenofovir moves from mother to baby. Researchers used a special lab model that mimics the third trimester of pregnancy. The goal was to see if certain proteins or drug interactions affect how much tenofovir reaches the fetus.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tenofovir
What this could lead to
If successful, this could help doctors understand how tenofovir moves through the placenta, potentially leading to safer use of this drug during pregnancy.
What could go wrong
This is a lab study using donated placentas, not a treatment trial. Results may not fully reflect what happens in the body, and the study does not test any new drug or therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

369 people

The number who actually took part.

Started

Feb 2013

Finished

Jun 2020

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Pregnant women (at term \>37 to 41 weeks of gestational age) without complications during pregnancy

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Major Patients \> or = 18 years old * At term between 37 and 41 weeks of gestational age * Uncomplicated pregnancy * Informed Consent Form signed Exclusion Criteria: * Women HIV+, HBV+ or HBC+ * Women with cardiovascular diseases such as diabetes or preeclampsia, IUGR * Women who had taken medications during pregnancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pregnant women are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pregnant women

Contacts and locations

Locations

  • Maternité de Port Royal

    Paris, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.